US-based pharmacy retailer Walgreens Boots Alliance (WBA) has reported that its sales from continuing operations were $67.7bn in the first six months (H1) of the fiscal year 2022 (FY22).

The figure represents a 5.4% growth on a year-on-year basis.

WBA’s operating income from continuing operations during the six months to 28 February was $2.5bn, compared with $298m in the same period a year earlier.

The company’s H1 net earnings from continuing operations increased by $3.9bn to $4.5bn, while its earnings per share (EPS) from continuing operations increased by $4.54 to $5.15 year-over-year (YoY).

For the second quarter (Q2), which ended on 28 February, WBA saw its sales from continuing operations grow by 3.0% on a YoY basis to $33.8bn.

Its operating income from continuing operations in the quarter was $1.2bn, compared with $832m in the prior-year period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Adjusted operating income from the retailer’s continuing operations grew by 35.9% in the three-month period to $1.7bn on a constant currency basis.

WBA reported its net earnings declined to $883m compared with $922m in the same period of FY21, while adjusted net earnings from its continuing operations ‘surged’ by 25.8% to $1.4bn.

The company’s EPS from continuing operations also declined to $1.02 in Q2 from $1.06 in the same quarter a year ago.

WBA CEO Rosalind Brewer said: “Second quarter results demonstrated broad-based execution, driving strong comparable sales and robust earnings growth.

“We continue to make important strides along our strategic priorities, building a consumer-centric, technology-enabled healthcare enterprise at the centre of local communities.”

Earlier this year, WBA reported that sales from its continuing operations in Q1 2022 were $33.9bn, up from $31.4bn a year earlier.

The company generated an operating income of $1.3bn in the quarter, after recording a $535m loss in the same period of last year.